Corticosteroids for pneumonia

Corticosteroids for Community-Acquired Pneumonia.

Corticosteroids in severe pneumonia.

The mortality rate in severe community- or hospital-acquired pneumonia is very high, ranging 20-50%. Despite advances in antimicrobial therapy and supportive measures, this rate has not changed in recent years, suggesting that other factors are also responsible for the poor outcome. An abnormal increase in the local and systemic inflammatory response is associated with poor outcome, and this oc...

Efficacy of Corticosteroids in Community-acquired Pneumonia

Rationale: Some studies have shown a beneficial effect of corticosteroids in patients with community-acquired pneumonia (CAP), possibly by diminishing local and systemic antiinflammatory host response. Objectives: To assess the efficacy of adjunctive prednisolone treatment in patients hospitalized with CAP. Methods: Hospitalized patients, clinically and radiologically diagnosedwithCAPusingstand...

Corticosteroids and pneumonia: time to change practice.

Pneumonia is characterised by lung inflammation, with fluid filling the alveoli and preventing adequate oxygenation of the body, and can be acquired in the community or in hospital. In 2013, about one million children died from pneumonia, which was the leading cause of death in children aged 5 years or younger. Annually, 15 adults per 1000 visit a doctor for symptoms of community-acquired pneum...

Corticosteroids for community-acquired pneumonia: time to act!

The use of corticosteroids for the treatment of community-acquired pneumonia has been reported for almost 50 years. A recent systematic analysis of the relevant literature suggested that corticosteroids reduce the critical illness associated with community-acquired pneumonia. There is little doubt that a prolonged administration of a moderate dose of corticosteroids may alleviate the systemic i...